Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | WDR5 | P61964 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036258 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL15486702 | 0.86 | ALDH1A1 (0.65) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL425317 | 0.86 | ALDH1A1 (0.71) | ALDH1A1LMNAKMT2AMEN1CYP1A2 | |
| SCHEMBL10293457 | 0.85 | ALDH1A1 (0.70) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL1972566 | 0.85 | ALDH1A1 (0.75) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL10126992 | 0.85 | ALDH1A1 (0.71) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL853688 | 0.85 | ALDH1A1 (0.69) | ALDH1A1LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL10126964 | 0.85 | ALDH1A1 (0.73) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL28143334 | 0.84 | ALDH1A1 (0.79) | ALDH1A1LMNAKDM4EKMT2APOLB | |
| SCHEMBL264943 | 0.83 | ALDH1A1 (0.67) | ALDH1A1LMNAKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4526307-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | Soltego, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2025-01-09 | — | — | US | disclosed |
| WO-2023225097-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SOLTEGO, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences, S.R.L. (IT) | 2021-09-30 | — | — | US | disclosed |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
| US-9637497-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | Nerviano Medical Sciences, S.R.L. (IT) | 2017-05-02 | — | — | US | disclosed |
| US-8541429-B2 | Pyrazolo quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
| EP-1636236-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004104007-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340556-A1 | PYRIMIDOPYRIMIDONE COMPOUNDS AND METHODS OF USE THEREOF | SIK2, SIK1, SIK3 | ALDH1A1 2257/4885LMNA 3188/4885KDM4E 2776/4885 |
| US-20210300935-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3081/4885LMNA 2710/4885KDM4E 1031/4885 |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3106/4885LMNA 2756/4885KDM4E 1015/4885 |
| US-20190194214-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3106/4885LMNA 2756/4885KDM4E 1015/4885 |
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3106/4885LMNA 2756/4885KDM4E 1015/4885 |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3106/4885LMNA 2756/4885KDM4E 1015/4885 |
| US-20250011333-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | ALDH1A1 3081/4885LMNA 2710/4885KDM4E 1031/4885 |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP3K19 | ALDH1A1 3008/4885LMNA 2685/4885KDM4E 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.